| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
|
Fizazi, Karim
|
|
2014
|
15 |
9 |
p. 975-985
11 p.
|
artikel
|
| 2 |
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
|
Hills, Robert K
|
|
2014
|
15 |
9 |
p. 986-996
11 p.
|
artikel
|
| 3 |
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
|
Coleman, Robert
|
|
2014
|
15 |
9 |
p. 997-1006
10 p.
|
artikel
|
| 4 |
A new dawn for gemtuzumab ozogamicin?
|
Kharfan-Dabaja, Mohamed A
|
|
2014
|
15 |
9 |
p. 913-914
2 p.
|
artikel
|
| 5 |
Anglican bishops declare support for assisted dying
|
Cagney, Hannah
|
|
2014
|
15 |
9 |
p. e368-
1 p.
|
artikel
|
| 6 |
A treatment for activated B-cell-like DLBCL?
|
Zinzani, Pier Luigi
|
|
2014
|
15 |
9 |
p. 916-917
2 p.
|
artikel
|
| 7 |
Biomarkers in early breast cancer and beyond: who needs all those tests?
|
Storz-Pfennig, Philipp
|
|
2014
|
15 |
9 |
p. 919-920
2 p.
|
artikel
|
| 8 |
Cancer care for refugees
|
Smith, James
|
|
2014
|
15 |
9 |
p. e363-e364
nvt p.
|
artikel
|
| 9 |
Cancer treatment disparities in US patients with HIV
|
Burki, Talha Khan
|
|
2014
|
15 |
9 |
p. e367-
1 p.
|
artikel
|
| 10 |
Carcinogenicity of perfluorooctanoic acid, tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane sultone
|
Benbrahim-Tallaa, Lamia
|
|
2014
|
15 |
9 |
p. 924-925
2 p.
|
artikel
|
| 11 |
Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis
|
Patel, Samir H
|
|
2014
|
15 |
9 |
p. 1027-1038
12 p.
|
artikel
|
| 12 |
Children's cancer drugs cut into Australian hospital budgets
|
Kirby, Tony
|
|
2014
|
15 |
9 |
p. 923-
1 p.
|
artikel
|
| 13 |
Clive James
|
Coburn, Cassandra
|
|
2014
|
15 |
9 |
p. 930-
1 p.
|
artikel
|
| 14 |
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
|
Younes, Anas
|
|
2014
|
15 |
9 |
p. 1019-1026
8 p.
|
artikel
|
| 15 |
Combination of vemurafenib and cobimetinib in patients with advanced BRAF V600-mutated melanoma: a phase 1b study
|
Ribas, Antoni
|
|
2014
|
15 |
9 |
p. 954-965
12 p.
|
artikel
|
| 16 |
Combined inhibition of BRAF and MEK in melanoma patients
|
Infante, Jeffrey R
|
|
2014
|
15 |
9 |
p. 908-910
3 p.
|
artikel
|
| 17 |
Comics and medicine
|
Towey, Francesca
|
|
2014
|
15 |
9 |
p. 927-928
2 p.
|
artikel
|
| 18 |
Contralateral prophylactic mastectomy: incremental survival
|
Tanday, Sanjay
|
|
2014
|
15 |
9 |
p. e369-
1 p.
|
artikel
|
| 19 |
Correction to Lancet Oncol 2014; 15: 881
|
|
|
2014
|
15 |
9 |
p. e365-
1 p.
|
artikel
|
| 20 |
Correction to Lancet Oncol 2014; 15: 621
|
|
|
2014
|
15 |
9 |
p. e365-
1 p.
|
artikel
|
| 21 |
Correction to Lancet Oncol 2012; 13: 987
|
|
|
2014
|
15 |
9 |
p. e365-
1 p.
|
artikel
|
| 22 |
Correction to Lancet Oncol 2014; 15: 797
|
|
|
2014
|
15 |
9 |
p. e365-
1 p.
|
artikel
|
| 23 |
Dear Ross
|
Towey, Francesca
|
|
2014
|
15 |
9 |
p. 929-
1 p.
|
artikel
|
| 24 |
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
|
Weller, Michael
|
|
2014
|
15 |
9 |
p. e395-e403
nvt p.
|
artikel
|
| 25 |
Epigenetic test for breast cancer
|
Burki, Talha Khan
|
|
2014
|
15 |
9 |
p. e366-
1 p.
|
artikel
|
| 26 |
Exploiting interleukin 6 in multicentric Castleman's disease
|
Bower, Mark
|
|
2014
|
15 |
9 |
p. 910-912
3 p.
|
artikel
|
| 27 |
FDA likely to further restrict or ban morcellation
|
Brower, Vicki
|
|
2014
|
15 |
9 |
p. e369-
1 p.
|
artikel
|
| 28 |
Fertility drugs not linked to cancer risk
|
Tanday, Sanjay
|
|
2014
|
15 |
9 |
p. e367-
1 p.
|
artikel
|
| 29 |
GlobalRT: building a new radiotherapy community
|
Rodin, Danielle
|
|
2014
|
15 |
9 |
p. 926-
1 p.
|
artikel
|
| 30 |
Is charged particle therapy superior to photon therapy?
|
Koto, Masashi
|
|
2014
|
15 |
9 |
p. 918-919
2 p.
|
artikel
|
| 31 |
Leukaemia and lymphoma: why has survival improved?
|
Munro, Alastair J
|
|
2014
|
15 |
9 |
p. 906-907
2 p.
|
artikel
|
| 32 |
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
|
Droz, Jean-Pierre
|
|
2014
|
15 |
9 |
p. e404-e414
nvt p.
|
artikel
|
| 33 |
MEK1/2 inhibition delays progression of uveal melanoma
|
Gilbert, Judith A
|
|
2014
|
15 |
9 |
p. e366-
1 p.
|
artikel
|
| 34 |
Methylprednisolone in patients with cancer using opioids
|
Burki, Talha Khan
|
|
2014
|
15 |
9 |
p. e370-
1 p.
|
artikel
|
| 35 |
New proposals to improve US cancer care and control costs
|
Furlow, Bryant
|
|
2014
|
15 |
9 |
p. 921-922
2 p.
|
artikel
|
| 36 |
NHS privatisation: a step too far
|
The Lancet Oncology,
|
|
2014
|
15 |
9 |
p. 905-
1 p.
|
artikel
|
| 37 |
Outcomes for depressed patients with prostate cancer
|
Squiers, Will
|
|
2014
|
15 |
9 |
p. e370-
1 p.
|
artikel
|
| 38 |
Poor results for everolimus in patients with liver cancer
|
Burki, Talha Khan
|
|
2014
|
15 |
9 |
p. e368-
1 p.
|
artikel
|
| 39 |
Radioactive: the fall of the Soviet Union
|
Morgan, Jules
|
|
2014
|
15 |
9 |
p. 928-929
2 p.
|
artikel
|
| 40 |
Renewing interest in targeting angiogenesis in glioblastoma
|
Gilbert, Mark R
|
|
2014
|
15 |
9 |
p. 907-908
2 p.
|
artikel
|
| 41 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
|
Iveson, Timothy
|
|
2014
|
15 |
9 |
p. 1007-1018
12 p.
|
artikel
|
| 42 |
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
|
van Rhee, Frits
|
|
2014
|
15 |
9 |
p. 966-974
9 p.
|
artikel
|
| 43 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
|
Taal, Walter
|
|
2014
|
15 |
9 |
p. 943-953
11 p.
|
artikel
|
| 44 |
Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study
|
Sant, Milena
|
|
2014
|
15 |
9 |
p. 931-942
12 p.
|
artikel
|
| 45 |
Systemic treatment for BRAF-mutant melanoma: where do we go next?
|
Menzies, Alexander M
|
|
2014
|
15 |
9 |
p. e371-e381
nvt p.
|
artikel
|
| 46 |
Targeting the HGF/MET pathway in gastric cancer
|
Lordick, Florian
|
|
2014
|
15 |
9 |
p. 914-916
3 p.
|
artikel
|
| 47 |
The South African National Cancer Registry: an update
|
Singh, Elvira
|
|
2014
|
15 |
9 |
p. e363-
1 p.
|
artikel
|
| 48 |
Translational implications of somatic genomics in acute myeloid leukaemia
|
Meyer, Sara C
|
|
2014
|
15 |
9 |
p. e382-e394
nvt p.
|
artikel
|
| 49 |
Will new AR inhibitors reshape the prostate cancer landscape?
|
Tombal, Bertrand
|
|
2014
|
15 |
9 |
p. 912-913
2 p.
|
artikel
|
Tijdschrift beschrijving